News from Zyme and the companies we work with.
Broken String Biosciences appoints Bruce Eaton PhD as Chairman of the Board
Strengthens Board with experienced industry executive, specializing in strategic planning, organizational leadership and commercial execution Cambridge, UK, 16 June 2026 – Broken String Biosciences, a biotechnology company enabling gene editing [...]
Laverock Therapeutics reports key oncology research milestones
London, UK, 10 June 2026: Laverock Therapeutics (‘Laverock’), a biotechnology company developing disease-responsive advanced therapies through its unique, programmable gene control technology, today announced key in-vivo functional milestones across its [...]
PhoreMost announces lead oncology programme and appoints Chief Medical Officer to support clinical entry
Next-generation small molecule microtubule targeting agent, PMC-001, progressing towards Phase 1 Comprehensive preclinical data package demonstrates differentiating oral activity and CNS penetration, unlocking treatment of primary and secondary brain cancers [...]
Bio-Rad Receives MicroVal Validation for EZ-CheckTM Listeria spp. and EZ-Check Listeria monocytogenes Testing Kits
Methods Certified by MicroVal for Detection of Listeria spp. and Listeria monocytogenes in Food and Environmental Samples HERCULES, Calif. June 02, 2026 — Bio-Rad Laboratories, Inc. (NYSE: BIO and BIO.B), [...]
Diagnostics start-up LotusDx establishes R&D laboratory at ONE BioHub to advance at-home STI testing
Dedicated R&D space to accelerate development of at-home testing to provide discreet, simple and fast solutions for sexually transmitted infections ONE BioHub’s location and connectivity will facilitate ongoing clinical engagement [...]
Laverock Therapeutics awarded in excess of £2.2M through two innovation grants to support AI-powered platform development and to expand therapeutic programmes outside of oncology
Grants totalling in excess of £2.2M awarded from two industry leading innovation funds The new grants will support the development of Laverock’s single-cell and AI powered gene-control platform, alongside pipeline [...]
Combat Medical highlights patient impact of HIVEC HEAT trial at the American Urological Association Annual Meeting
MHRA-approved phase 3 study is investigating intravesical delivery of hyperthermic chemotherapy in bladder-sparing treatment of patients with non-muscle invasive bladder cancer Study being conducted across 25 sites in the UK [...]
SLAS Celebrates Innovative New Products, Startups and Scientific Excellence at European Conference in Vienna
SLAS Celebrates Innovative New Products, Startups and Scientific Excellence at European Conference in Vienna Vienna, Austria, 26 May 2026: SLAS, the Society of Laboratory Automation and Screening, after a six-year [...]
Tecan establishes direct sales and specialist lab automation service operations in India
Strengthening local presence and customer support in a high-growth life sciences market Männedorf, Switzerland, May 26, 2026:Tecan (SIX Swiss Exchange: TECN), a global provider of laboratory automation and solutions, today [...]
OutSee selected for Discovery Award from Longitude Prize on ALS to accelerate AI-based target discovery
Funding to identify novel targets for ALS treatment using OutSee’s ‘genomics first’ target discovery platform, Nomaly Provides access to world’s largest and most comprehensive ALS patient dataset Part of £7.5M [...]
Cyclana Bio granted Health Research Authority approval and recruits first patients for clinical observational study in endometriosis
UK NHS grants HRA/REC approval for PEMP study with Peterborough and Cambridge hospitals Clinical observational study investigating underlying biology of endometriosis aims to uncover causal mechanisms and new druggable targets [...]
Qureight to support Mediar Therapeutics’ Phase 2 trial of MTX-474 in diffuse cutaneous Systemic Sclerosis
Qureight’s AI-powered quantitative imaging analytics platform and services to analyse HRCT images to evaluate changes in compartment-specific lung biomarkers The focus of these efforts will be on the quantitative assessment [...]
